ReviewTrends in pharmacological sciences2013
Mechanisms of dopamine transporter regulation in normal and disease states.
Review in Trends in pharmacological sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 225 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
225 citing papers in PubMed, 1 synthesis or guideline pooled it, 410 citations in OpenAlex.
- Non-invasive Brain Stimulation for Gambling Disorder: A Systematic Review.Frontiers in neuroscience · 2020Pooled it
- Presence of recombination hotspots throughout SLC6A3.PloS one · 2019Trial
- The SLC-ome of membrane transport: from molecular discovery to physiology and clinical applications.Physiological reviews · 2026Review
- GBR 12909, a Selective Dopamine Transporter Inhibitor, Differentially Modulates Affective, Exploratory and Cognitive Domains in Zebrafish.The European journal of neuroscience · 2026Article
- Unraveling the enigma: Post-translational modifications in psychiatric disorders and their regulatory mechanisms.Journal of translational internal medicine · 2026Article
- Sex and ovarian hormone cycles alter effects of stimulant drugs on mouse dopaminergic signaling.The Journal of clinical investigation · 2026Article
- Age at onset of Parkinson's disease modulates the sphingolipid-dopaminergic interplay in autonomic progression.NPJ Parkinson's disease · 2026Article
- Analysis of Metabolic Differences and Core Regulatory Pathways in Lactic Acid Bacteria-Fermented Broths of DifferentFoods (Basel, Switzerland) · 2026Article
- Alpha-methyl-para-tyrosine and amphetamine ameliorate hyperactivity in a novel mouse model of dopamine transporter deficiency syndrome.EMBO molecular medicine · 2026Article
- NDST3-Induced Epigenetic Reprogramming Reverses Neurodegeneration in Parkinson's Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- MicroRNA-132/212 negatively modulates opioid reward by targeting dopamine transporter in the ventral tegmental area.Translational psychiatry · 2026Article
- Multicolor Quantum Dot Tracking Uncovers Phenotypic Rescue of DAT A559V Aberrant Diffusion Upon D2R Antagonism.ACS chemical neuroscience · 2026Article
- Article
- The radiotracer [Annals of nuclear medicine · 2026Review
- PMAT enhances sexual dimorphism of fear behaviors and facilitates female mice's generalized contextual fear extinction.Frontiers in neuroscience · 2026Article
- Exercise modulates food reward: neurobiological mechanisms and implications for weight management.Frontiers in nutrition · 2026Review
- Apathy and Reduced Voluntary Activity in Older Adults with Parkinson's Disease: Mechanisms, Clinical Assessment, and Rehabilitation Implications.Clinical interventions in aging · 2026Review
- Ontogeny of Catechol-O-Methyltransferase Expression in the Rat Prefrontal Cortex: Effects of Methamphetamine Exposure.Developmental neuroscience · 2026Article
- Amphetamine-type stimulants in young adults with ADHD: effects on sleep, circadian rhythms, and neuropsychiatric outcomes.Frontiers in pharmacology · 2026Review
- The Change of Dopamine Transporter After Glucose Loading Is Associated With an Individual's Attitude Toward Sweet Foods in Healthy Young Males.Human brain mapping · 2025Article
165 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The dopamine (DA) transporter (DAT) controls the spatial and temporal dynamics of DA neurotransmission by driving reuptake of extracellular transmitter into presynaptic neurons. Many diseases such as depression, bipolar disorder, Parkinson's disease (PD), and attention deficit hyperactivity disorder (ADHD) are associated with abnormal DA levels, implicating DAT as a factor in their etiology. Medications used to treat these disorders and many addictive drugs target DAT and enhance dopaminergic signaling by suppressing transmitter reuptake. We now understand that the transport and binding properties of DAT are regulated by complex and overlapping mechanisms that provide neurons with the ability to modulate DA clearance in response to physiological demands. These processes are controlled by endogenous signaling pathways and affected by exogenous transporter ligands, demonstrating their importance for normal neurotransmission, drug abuse, and disease treatments. Increasing evidence supports the disruption of these mechanisms in DA disorders, implicating dysregulation of transport in disease etiologies and suggesting these processes as potential points for therapeutic manipulation of DA availability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.